Figure 1From: HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients Changing characteristic of HBsAg in SC or non-SC patients during treatment. The changing profile of serum HBsAg (log10 IU/ml) level of each patient was classified to SC (A) or non-SC patients (B) during TDF treatment for 96Â weeks.Back to article page